6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

Jan 21 2010

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6^th Annual Diabetes Conference in London, on Friday, January 22.

In his presentation Dr. Ashton will describe the barriers to clinically effective therapies in diabetic retinopathy and the difficulty of getting drugs to the back of the eye, where most diabetic eye disease manifests itself. He is expected to discuss emerging drug delivery technologies, including those under development at pSivida, which can help to get drugs directly to the area of the eye where they can be most effective in treating the underlying disease. As part of this presentation, Dr. Ashton is also expected to recap recent top-line results of the Phase 3 FAME™ trials of Iluvien® in patients with diabetic macular edema that were reported last month by pSivida and its licensee, Alimera Sciences.

Also scheduled to address the two-day conference are representatives from GlaxoSmithKline, Sanofi-Aventis, Merck Sharp & Dohme, F. Hoffman-LaRoche, AstraZeneca, Lilly, Astellas, Regeneron Pharmacuegticals, Medpace and Fovea Pharmaceuticals, and leading ophthalmologists from the University of Oxford and Moorfields Eye Hospital.